ArticleJAMA oncology2025

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.

Kirithiga Ramalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.